206 related articles for article (PubMed ID: 18570597)
1. Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients.
Nakou E; Filippatos TD; Liberopoulos EN; Tselepis AD; Kiortsis DN; Mikhailidis DP; Elisaf MS
Expert Opin Pharmacother; 2008 Jul; 9(10):1629-39. PubMed ID: 18570597
[TBL] [Abstract][Full Text] [Related]
2. Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study.
Scholze J; Grimm E; Herrmann D; Unger T; Kintscher U
Circulation; 2007 Apr; 115(15):1991-8. PubMed ID: 17404163
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
Derosa G; Cicero AF; Murdolo G; Piccinni MN; Fogari E; Bertone G; Ciccarelli L; Fogari R
Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
[TBL] [Abstract][Full Text] [Related]
4. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients.
Faria AN; Ribeiro Filho FF; Kohlmann NE; Gouvea Ferreira SR; Zanella MT
Diabetes Obes Metab; 2005 May; 7(3):246-53. PubMed ID: 15811141
[TBL] [Abstract][Full Text] [Related]
5. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
Pepine CJ; Handberg EM; Cooper-DeHoff RM; Marks RG; Kowey P; Messerli FH; Mancia G; Cangiano JL; Garcia-Barreto D; Keltai M; Erdine S; Bristol HA; Kolb HR; Bakris GL; Cohen JD; Parmley WW;
JAMA; 2003 Dec; 290(21):2805-16. PubMed ID: 14657064
[TBL] [Abstract][Full Text] [Related]
6. Preclinical considerations and results with the combination of verapamil and trandolapril: blood pressure reduction and beyond.
Kirchengast M
J Hypertens Suppl; 1997 Mar; 15(2):S27-33. PubMed ID: 9218195
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension. Swedish TARKA trialists.
Karlberg BE; Andrup M; Odén A
Blood Press; 2000; 9(2-3):140-5. PubMed ID: 10855738
[TBL] [Abstract][Full Text] [Related]
8. Comparison of different fixed antihypertensive combination drugs: a double-blind, placebo-controlled parallel group study.
de Leeuw PW; Notter T; Zilles P
J Hypertens; 1997 Jan; 15(1):87-91. PubMed ID: 9050975
[TBL] [Abstract][Full Text] [Related]
9. The fixed combination of verapamil SR/trandolapril.
Widimský J
Expert Opin Pharmacother; 2000 Mar; 1(3):515-35. PubMed ID: 11249535
[TBL] [Abstract][Full Text] [Related]
10. Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension.
Muijsers RB; Curran MP; Perry CM
Drugs; 2002; 62(17):2539-67. PubMed ID: 12421112
[TBL] [Abstract][Full Text] [Related]
11. Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlortalidone treatment in hypertensive type 2 diabetes.
Schneider M; Lerch M; Papiri M; Buechel P; Boehlen L; Shaw S; Risen W; Weidmann P
J Hypertens; 1996 May; 14(5):669-77. PubMed ID: 8762212
[TBL] [Abstract][Full Text] [Related]
12. Effects of verapamil SR, trandolapril, and their fixed combination on 24-h blood pressure: the Veratran Study.
Veratran Study Group
Am J Hypertens; 1997 May; 10(5 Pt 1):492-9. PubMed ID: 9160758
[TBL] [Abstract][Full Text] [Related]
13. [The TEAM study--a study of the effectiveness and tolerance of treatment of essential hypertension with a fixed combination of trandolapril and verapamil].
Widimský J; Dzúrik R
Vnitr Lek; 1998 Jun; 44(6):326-31. PubMed ID: 9820054
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
16. Once-daily fixed dose combinations of verapamil and trandolapril in black patients with mild to moderate hypertension: a new choice for first line treatment.
Skoularigis J; Strugo V; Radevski I; Hlatswayo Z; Sareli P
Int J Clin Pharmacol Ther; 1997 Feb; 35(2):51-5. PubMed ID: 9147707
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of combination therapy with trandolapril and verapamil sr in primary hypertension: a 4 x 4 trial design. The Trandolapril Study Group.
DeQuattro V; Lee D; Messerli F
Clin Exp Hypertens; 1997 Apr; 19(3):373-87. PubMed ID: 9107443
[TBL] [Abstract][Full Text] [Related]
18. Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension.
Reynolds NA; Wagstaff AJ; Keam SJ
Drugs; 2005; 65(13):1893-914. PubMed ID: 16114984
[TBL] [Abstract][Full Text] [Related]
19. Fixed combination verapamil SR/trandolapril.
Dooley M; Goa KL
Drugs; 1998 Nov; 56(5):837-44; discussion 845-6. PubMed ID: 9829157
[TBL] [Abstract][Full Text] [Related]
20. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
